Manuel Piechutta

ORCID: 0000-0002-0122-3244
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Brain Metastases and Treatment
  • Glioma Diagnosis and Treatment
  • Immune cells in cancer
  • Neuroinflammation and Neurodegeneration Mechanisms
  • Immunotherapy and Immune Responses
  • Nanoplatforms for cancer theranostics
  • Cancer Immunotherapy and Biomarkers
  • Chemokine receptors and signaling
  • CAR-T cell therapy research
  • Barrier Structure and Function Studies
  • Ferroptosis and cancer prognosis
  • Extracellular vesicles in disease
  • Lung Cancer Research Studies
  • bioluminescence and chemiluminescence research
  • Medical Imaging Techniques and Applications

Heidelberg University
2018-2024

German Cancer Research Center
2018-2024

National Center for Tumor Diseases
2018-2020

University Hospital Heidelberg
2018-2020

University of Bonn
2019

Rationale: Glioblastoma is the most frequent, primary brain tumor that characterized by a highly immunosuppressive microenvironment (TME). The TME plays key role for biology and effectiveness of immunotherapies. Composition correlates with overall survival governs therapy response. Non invasive assessment has been notoriously difficult. Methods: We have designed an in vivo imaging approach to non invasively visualize innate immune cell dynamics mouse glioma model correlated MRI multiphoton...

10.7150/thno.38659 article EN cc-by Theranostics 2020-01-01

To improve immunotherapy for brain tumors, it is important to determine the principal intracranial site of T cell recruitment from bloodstream and their route tumors. Using intravital microscopy in mouse models melanoma, we discovered that circulating cells preferably adhered extravasated at a distinct type venous blood vessel tumor vicinity, peritumoral vessels (PVVs). Other vascular structures were excluded as alternative routes melanomas. Anti-PD-1/CTLA-4 immune checkpoint inhibitors...

10.1016/j.immuni.2024.09.003 article EN cc-by Immunity 2024-10-04

Abstract Brain metastases (BM) are an ever-increasing challenge in oncology, threatening quality of life and survival many cancer patients. The majority BM originate from lung adenocarcinoma, stage III patients have a risk 40–50% to develop the first years disease onset. As therapeutic options limited, prevention their occurrence is attractive concept. Here we investigated whether Nintedanib (BIBF 1120), tyrosine kinase inhibitor (TKI) targeting VEGF pathway approved for dual...

10.1007/s10585-020-10055-x article EN cc-by Clinical & Experimental Metastasis 2020-09-12

Despite high frequency of brain metastases (BM) in patients with advanced tumor stages and the process that immunotherapy becomes treatment choice these cases, activity mechanisms adaptive immune response BM is poorly understood. Current knowledge on immunological microenvironment gained from vitro- ex vivo experiments, such as flow cytometry immunohistochemistry. However, methods fail to recapitulate dynamic influx lymphocytes their interaction cells complex microenvironment. A better...

10.1093/neuonc/noy139.218 article EN Neuro-Oncology 2018-09-01

Brain metastases (BM) are a devastating and frequent complication in patient with metastatic cancer. Survival is severely limited as the current treatment strategies have to conquer several obstacles symptomatic BM including heterogenous composition of blood-brain barrier altered microenvironment characteristics. “Prevent_BM” collaborative effort five research groups, both clinical pre-clinical, identify concept targeting formation early preventing outgrowth macro-metastases. In Prevent_BM,...

10.1093/neuonc/noy139.223 article EN Neuro-Oncology 2018-09-01

One major challenge in glioma immunotherapy is to ensure homing of peripherally activated adaptive immune cells the tumor while retaining their effector function. For systemic tumors, local irradiation has been shown induce a proinflammatory chemokine and cytokine milieu which facilitates infiltration cells. Within CNS, molecular mechanisms mediating irradiation-induced modulation leukocyte function are only poorly understood but essential exploit radiotherapy as immunological adjuvant for...

10.1093/neuonc/noy139.268 article EN Neuro-Oncology 2018-09-01

Despite high frequency of brain metastases (BM) in patients with advanced tumor stages and immunotherapy becoming the treatment choice these cases, mechanisms adaptive immune response BM is poorly understood. Current knowledge on immunological microenvironment gained from vitro- ex vivo experiments. However, methods fail to recapitulate dynamic influx lymphocytes their interaction cells complex microenvironment. A better understanding lymphocyte recruitment, trafficking activation urgently...

10.1093/neuonc/noy148.529 article EN Neuro-Oncology 2018-11-01

Abstract Immune checkpoint therapy has demonstrated potential for the treatment of brain metastases, but mechanisms lymphocyte recruitment to tumors are poorly understood. To monitor T cell infiltration and tumor growth in vivo real time, we performed intravital microscopy adoptively transferred endogenous cells mouse models intracranial melanoma. By spatio-temporal analysis dynamics could identify a distinct type venous blood vessels vicinity, “peritumoral vessels” (PVVs). Intraluminal...

10.1158/1538-7445.am2022-2487 article EN Cancer Research 2022-06-15
Coming Soon ...